NIH Issues Parent R01, R21 Clinical Trial Funding Opportunities

As you should know by now, NIH is overhauling the submission process for applications due on or after January 25, 2018, that include a clinical trial. For such applications, you must:

NIAID plans to discontinue its R01 FOA—NIAID Clinical Trial Implementation Grant (R01)—and in its place use two new NIH clinical trial FOAs for investigator-initiated research:

NIAID recommends that you use these FOAs only for low-risk clinical trials, and we encourage you to instead use the NIAID Clinical Trial Implementation Cooperative Agreement (U01) for high-risk trials. Refer to the U01 FOA for a definition of high-risk clinical trials.

To optimize your chances of success and leverage NIAID’s Investigator-Initiated Clinical Trial Resources, we recommend that you contact an NIAID program officer at least 10 weeks before applying. See Contacts and Special Interests to find an appropriate program division contact.

Keep in mind: clinical trials are complicated, as are components of the application—study design, risk to participants, feasibility, and budget. Missing or inadequate information could result in your application being withdrawn before review or not funded even after receiving a meritorious score.

Be absolutely certain that your budget is sufficient to support the proposed research. Applicants who request a single year budget of $500,000 or more must receive prior approval following the process explained in our Big Grants SOP.

Even if your application’s budget request is under the $500,000 threshold, prior consultation with an NIAID program officer is still the best way to ensure you aren’t wasting time developing an application that is either incomplete or not a priority to NIAID.

Content last reviewed on December 6, 2017

Browse all Articles